First, the direct answer. If you have an anxiety disorder (generalised anxiety, panic disorder, social anxiety), and the standard treatments have not been enough, the honest European picture in 2026 is this: the established next steps are refinements of standard care, not psychedelics. The guideline ladder runs through proper cognitive behavioural therapy, SSRIs and SNRIs at adequate dose and duration, medication switches, pregabalin for generalised anxiety, combinations and specialist augmentation. Ketamine for anxiety is early-stage research, not an established route, and no psychedelic is approved for any anxiety disorder anywhere in Europe. This page walks the real ladder first, then gives a sober account of exactly where the experimental options stand, because you will meet them in advertising long before you meet them in a guideline.
One reassurance before the list. Partial response is common in anxiety care, and the reference guidelines this page leans on: the UK's NICE guideline CG113 for generalised anxiety and panic disorder and Germany's S3-Leitlinie for anxiety disorders; plan explicitly for the next step after a treatment that has not worked. Nothing here is a recommendation of one option over another; which step fits you is a decision for you and a clinician who knows your history.
TL;DR The guideline ladder for anxiety that hasn't responded: first check what "tried" really means; a full CBT course with a trained therapist and an SSRI/SNRI at adequate dose for at least several weeks are both frequently under-delivered. Then: switch within or between medication classes; pregabalin as an established GAD option; combine psychotherapy with medication if you had only one; specialist augmentation after that. Ketamine: small early trials only, no approval for anxiety; esketamine's EU licence is for treatment-resistant depression. Psychedelics: no approved anxiety indication in Europe, few anxiety-specific trials. If anxiety and depression overlap, the depression ladder is better mapped; start with a diagnostic re-examination.
What the options actually are
Step one is an audit, not a new treatment. Anxiety care fails most often in delivery, not in the toolbox. A genuine course of CBT means a structured protocol with a trained therapist over weeks, not general supportive counselling. An adequate medication trial means the right dose held long enough: anxiety disorders often respond more slowly than depression, and stopping at week three tells you nothing. Write down what you have actually had: substance, dose, duration, outcome, and what kind of therapy, with whom. Every serious clinician starts there, and so does every door below.
The medication ladder. SSRIs and SNRIs are first-line across the European guidelines. After a failed adequate trial, the established moves are a switch to another SSRI or to an SNRI; for generalised anxiety disorder, pregabalin is an approved, guideline-listed alternative with a different mechanism. Benzodiazepines remain short-term, crisis-window tools in the guidelines, not a maintenance answer, and if you have been on one long-term, that conversation belongs in the plan too. Beyond this, augmentation strategies exist at the specialist level; they are individual decisions, not a menu.
Psychotherapy, done properly, and the combination. If you have only had medication, adding CBT is not a repeat: it is the other half of first-line care, and the combination outperforms either alone for many people. Exposure-based methods for panic and social anxiety are specific skills; it is fair to ask a therapist directly about their training in them.
When it is not (only) anxiety. Anxiety that resists treatment is often anxiety plus depression, or depression presenting as anxiety. This matters practically, because the treatment-resistant depression pathway is far better mapped in Europe, including esketamine, an approved option with defined criteria. If your low mood is as persistent as your worry, a diagnostic re-examination opens doors this page's ladder does not: start with depression treatment isn't working: your options.
Where ketamine actually stands for anxiety
Bluntly: nowhere established. The evidence base for ketamine in anxiety disorders is a handful of small, mostly early-phase studies; the European approval of esketamine (Spravato) covers treatment-resistant depression (with anxiety at most present as a comorbidity), and no European guideline lists ketamine as an anxiety treatment. Clinics do offer it: legally that is off-label practice, which is permitted with justification in most European countries, but a trustworthy provider will tell you unprompted that the anxiety evidence is thin and will screen for the depression that may actually be driving the picture. What the ketamine evidence does and does not show, condition by condition, is in our ketamine evidence review; how to recognise a careful clinic is in the choosing-a-clinic guide.
Where psychedelics actually stand for anxiety
No psychedelic (psilocybin, MDMA, LSD) is an approved treatment for any anxiety disorder anywhere in Europe. The research wave targets depression first, PTSD second, and end-of-life distress; anxiety-specific European trials are rare, so treat any "psychedelic therapy for anxiety" offer against that fact. The genuinely legal doors in Europe today are clinical trials, check the recruiting-trials index for what is actually open, and, for Swiss residents only, the Swiss limited-medical-use programme, case by case at the treating physician's application. The wider map, substance by substance, is in where in Europe you can actually get psychedelic therapy.
How to work out where you are
Three questions organise everything. What have I actually had (in writing, with doses, durations and therapy types? Is my diagnosis still the right frame) anxiety, depression, or both? And what is the next guideline step from here, not the next advertised step? Take those three to a psychiatrist or to your GP for referral. If part of your picture is treatment-resistant depression, our eligibility check can organise the access side: it compares your answers with published access criteria, is not a diagnosis, and the formal eligibility decision always happens with the treating clinician.
Frequently asked questions
Can ketamine treat anxiety?
It is not an approved or guideline-established treatment for anxiety disorders in Europe. Small early studies exist; esketamine's European licence is for treatment-resistant depression. Clinics offering ketamine for anxiety are treating off-label on limited evidence: legal with justification, but ask directly what evidence they cite and whether depression has been assessed.
Is any psychedelic approved for anxiety in Europe?
No. Psilocybin, MDMA and LSD have no approved anxiety indication anywhere in Europe. Research focuses on depression, PTSD and end-of-life distress; anxiety-specific European trials are rare. The legal routes to psychedelics remain clinical trials and, for Swiss residents, the Swiss limited-medical-use programme.
I've tried an SSRI and therapy: what's actually next?
Per the UK and German guidelines: check both were adequate (dose, duration, real CBT); then switch medication class or, for GAD, consider pregabalin; combine therapy and medication if you had only one; then specialist augmentation. If depression is part of the picture, the treatment-resistant depression pathway (which includes esketamine with defined criteria) may be the better-mapped door.
Where do I start if I want a professional to look at all of this?
With your written treatment history and either your GP or a psychiatrist. If treatment-resistant depression is in play, the depression options guide maps that ladder, and our directory lists verified providers by country for the access step.
Sources
- NICE CG113, Generalised anxiety disorder and panic disorder in adults: nice.org.uk
- AWMF S3-Leitlinie Angststörungen (Germany): register.awmf.org
- EMA: Spravato (esketamine) approved indication: ema.europa.eu
- PsyAccess ketamine evidence review (what the trials show, condition by condition): /guides/ketamine-evidence/
- PsyAccess recruiting-trials index (updated from CTIS/ClinicalTrials.gov): /guides/psychedelic-trials-recruiting-europe/